50 min
The iterative nature of emerging therapeutics Molecule to Market: Inside the outsourcing space
-
- Life Sciences
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jennifer Chadwick, CSO of ProtaGene.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jennifer, covering:
Lessons and learnings moving from the world of academia into commercial industry
The shift from lowest-price tactical outsourcing to value-based, holistic, and strategic outsourcing at a much earlier stage
Nuances in the sandbox of playing with the buckets of CGTPs, and why emerging therapeutics do not play by the rules
The increasing importance of risk-based assessment in early-stage drug development, and the need to increase the bar for understanding complex modalities in a smart, cost-effective and efficient way as we begin to understand them more
Jennifer Chadwick is Chief Scientific Officer of ProtaGene and serves as Site Head in Boston. She brings two decades of experience leading scientific teams in the biotech industry and academia and is a well-recognized expert in development of biologics and gene therapy products.
She served as Vice President of Analytical Development and of Biologic Development at BioAnalytix. Previously, Dr. Chadwick was a tenured Professor of Pharmaceutical Chemistry at the University of Kansas.
Jen has authored thought leadership articles related to analytical development of gene therapy products and published approximately 75 peer-reviewed publications, 13 patents, and four book chapters, demonstrating her expertise and deep understanding of biologics and drug development.
Dr. Chadwick has served as an Associate Director of CASSS and a member of the Steering Committee for academic-industry relations at the Massachusetts Biotechnology Council. She is also a Visiting Scholar in the Department of Chemistry and Chemical Biology at Northeastern University. She received her PhD from Purdue University Department of Chemistry.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jennifer Chadwick, CSO of ProtaGene.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jennifer, covering:
Lessons and learnings moving from the world of academia into commercial industry
The shift from lowest-price tactical outsourcing to value-based, holistic, and strategic outsourcing at a much earlier stage
Nuances in the sandbox of playing with the buckets of CGTPs, and why emerging therapeutics do not play by the rules
The increasing importance of risk-based assessment in early-stage drug development, and the need to increase the bar for understanding complex modalities in a smart, cost-effective and efficient way as we begin to understand them more
Jennifer Chadwick is Chief Scientific Officer of ProtaGene and serves as Site Head in Boston. She brings two decades of experience leading scientific teams in the biotech industry and academia and is a well-recognized expert in development of biologics and gene therapy products.
She served as Vice President of Analytical Development and of Biologic Development at BioAnalytix. Previously, Dr. Chadwick was a tenured Professor of Pharmaceutical Chemistry at the University of Kansas.
Jen has authored thought leadership articles related to analytical development of gene therapy products and published approximately 75 peer-reviewed publications, 13 patents, and four book chapters, demonstrating her expertise and deep understanding of biologics and drug development.
Dr. Chadwick has served as an Associate Director of CASSS and a member of the Steering Committee for academic-industry relations at the Massachusetts Biotechnology Council. She is also a Visiting Scholar in the Department of Chemistry and Chemical Biology at Northeastern University. She received her PhD from Purdue University Department of Chemistry.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.
50 min